



3rd Symposium for Emerging Viral Diseases

Campus Biotech, Geneva, Switzerland, 7-9 December

2022 <https://www.unige.ch/emerging-virus-symposium/>

Benjamin Meyer :

“Locking the Entry Door of SARS-CoV-2, are Mucosal Antibodies the Key?”



Main affiliation:

University of Geneva, Switzerland

Actual Position:

Scientific collaborator

Web site :

<https://www.unige.ch/medecine/fr/>

I received training in virology at the laboratory of Prof. Christian Drosten at the University of Bonn Medical Centre from 2011 to 2016, where I also completed my PhD in 2015. After a short work experience outside of academia at the R&D department of the biotech company PEPperPRINT in Heidelberg, I joined the laboratory of Prof. Claire-Anne Siegrist at the Center of Vaccinology at the University of Geneva in 2019, where I worked on the interface between virology and immunology. Since 2021, I hold an Ambizione fellowship from the SNSF and head my own group at the Department of Pathology and Immunology at the University of Geneva. My main research interest focuses on the systemic and mucosal immune response in humans after infection or vaccination with respiratory viruses such as influenza virus and SARS-CoV-2. Specifically, I study the influence of systemic and mucosal immunity on virological, i.e. infectious and RNA viral load, and clinical outcomes, i.e. symptom strength and duration. Therefore, I combine well-designed human clinical trials with state-of-the-art immunological and virological laboratory analysis to achieve new insights in how the immune systems prevents or controls infections of respiratory viruses. By investigating the mechanisms behind immune protection from infection or severe disease will guide the development of new and improved vaccines.